Ultomiris shows strong interim results in Phase III IgA nephropathy trial

IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys

Pfizer unleashes wave of breakthrough cancer data at ASCO 2026

Pharma giant targets new standards of care

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Asahi Kasei pushes into human trials with new autoimmune drug candidate

The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp

Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion

If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev

Centre of Excellence by Terumo India, AIG Hospitals to bridge IR skill gaps and reduce procedural risks

The programme integrates simulation-based training, expert-led sessions, and case-based discussions

Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%

The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints

Moderna launches late-stage trial of mRNA bird flu vaccine

The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone

ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche

The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents

Global warming threatens health, environment and economic stability: Dr Jitendra Singh

The Union Minister noted that heat stress contributes to a rise in both communicable diseases such as dengue and non-communicable conditions like cardiovascular disorder